Conjugated anti-cd38 antibodies
AssigneeTakeda Pharmaceutical Company Limited
InventorsKathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
Life of this patent
Estimating the term…
Abstract
Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
Claims21
An isolated antibody which specifically binds human CD38 (SEQ ID NO:1) and cynomolgus CD38 (SEQ ID NO:2) comprising:
- a) a heavy chain variable region comprising:
- i) a first CDR comprising SEQ ID NO:3;
- ii) a second CDR comprising SEQ ID NO:4;
- iii) a third CDR comprising SEQ ID NO:5;
- and
- b) a light chain variable region comprising:
- i) a first CDR comprising SEQ ID NO:6;
- ii) a second CDR comprising SEQ ID NO:7;
- iii) a third CDR comprising SEQ ID NO:8;
- and
- c) a covalently attached drug moiety.
An isolated antibody which specifically binds human CD38 (SEQ ID NO:1) and cynomolgus CD38 (SEQ ID NO:2) comprising:
- a) a heavy chain variable region comprising:
- i) a first CDR comprising SEQ ID NO:13;
- ii) a second CDR comprising SEQ ID NO:14;
- iii) a third CDR comprising SEQ ID NO:15;
- and
- b) a light chain variable region comprising:
- i) a first CDR comprising SEQ ID NO:16;
- ii) a second CDR comprising SEQ ID NO:17;
- iii) a third CDR comprising SEQ ID NO:18;
- and
- c) a covalently attached drug moiety.
An isolated antibody according to any of the previous claims wherein said drug moiety is attached to said antibody using a linker.
An isolated nucleic acid encoding the light chain of 3 or 8.
A method of inhibiting the biological activity of human CD38 protein (SEQ ID NO:
- 1) and cynomolgus CD38 (SEQ ID NO:2) by contacting said protein with an antibody that interacts with at least K121, F135, Q139, D141, E239, W241, C275, K276, F284, P291 and E292 of SEQ ID NO:1 and SEQ ID NO:2.
A method of treating cancer comprising administering to a patient in need thereof an isolated antibody which specifically binds human CD38 (SEQ ID NO:1) and cynomolgus CD38 (SEQ ID NO:2) comprising:
- a) a heavy chain variable region comprising:
- i) a first CDR comprising SEQ ID NO:3;
- ii) a second CDR comprising SEQ ID NO:4;
- iii) a third CDR comprising SEQ ID NO:5;
- and
- b) a light chain variable region comprising:
- i) a first CDR comprising SEQ ID NO:6;
- ii) a second CDR comprising SEQ ID NO:7;
- iii) a third CDR comprising SEQ ID NO:8;
- and
- c) a covalently attached drug moiety.
Dependencies are inferred from the claim text.